Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children
- Conditions
- Asthma
- Registration Number
- NCT00094016
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Brief Summary
The primary objective of this study is to compare the QVAR-Easi-Breathe 100 mcg/day and QVAR-Easi-Breathe 200 mcg/day with placebo relative to changes in forced expiratory volume in 1 second (FEV1) results following 12 weeks of treatment. Secondary objectives such as daily asthma symptoms scores (per week), morning peak expiratory flow (PEF) values, nocturnal awakening and utilization of rescue medication per day also will be evaluated. In addition, an exploratory evaluation will assess the comparability of the two devices (i.e., QVAR-Easi-Breathe versus QVAR-MDI) at the same dose levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 440
- Male or female children aged 5 through 11 years at the screening visit
- Documented clinical evidence of asthma (FEV1 = 65-90%)
- Ability to perform acceptable and reproducible spirometry per ATS guidelines
- Ability to perform PEF determinations
- Reversible bronchoconstriction as verified by >12% increase in FEV1
- Otherwise healthy children with clinically-acceptable medical history, physical examination, vital signs and clinical laboratory parameters within the acceptable ranges for asthma patients
- The parent or guardian must be willing to give written informed consent as well as the patient assent and be able to adhere to the dose and visit schedule.
-
Patients who have used inhaled corticosteroids within 30 days prior to the screening visit.
-
Allergy or sensitivity to beclomethasone dipropionate (BDP) or to other components of the formulations used in the CTM
-
Patients demonstrating an increase or decrease in FEV1 >20% between the screening and baseline visit.
-
Patients who are unable to use a metered dose inhaler (MDI) without a spacer device.
-
Patients requiring the use of >12 puffs per day of albuterol for any 3 consecutive days between the screening and baseline visits.
-
Patients with evidence of growth retardation
-
Patients who have been treated with methotrexate, cyclosporin, gold or other cytotoxic agents for the control of asthma or for a concurrent condition within the last 3 months.
-
Patients who are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy for rhinitis.
-
Patients with evidence (on physical exam) of oropharyngeal candidiasis.
-
Exposure to investigational drugs within 30 days prior to the screening visit
-
Require continuous treatment with beta blockers MAO inhibitors, tricyclic antidepressants, anticholinergics, inhaled nedocromil or cromolyn, or nebulized therapy (excluding sponsor provided albuterol MDI)
-
Inability to tolerate or unwillingness to comply with required washout periods for all applicable medications
-
Treatment at any time for life-threatening asthmatic episodes (e.g., episodes requiring intubation and/or associated with the development of hypercapnia, hypoxia and seizures, etc.)
-
Patients that have received any of the following treatments or met any of the following conditions within six weeks prior to the screening visit:
- Oral or injectable corticosteroids
- an upper respiratory tract infection and/or sinusitis associated with exacerbation of asthmatic symptoms
- emergency room treatment or hospitalization for asthmatic symptoms.
-
History and/or presence of any non-asthmatic acute or chronic lung disease, including but not limited to bronchitis (within the previous 6 months), emphysema, active tuberculosis, bronchiectasis or cystic fibrosis.
-
Presence of any clinically-significant cardiovascular disease (including cardiac arrhythmias and uncontrolled hypertension), clinically-significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled diabetes, hyperthyroidism, convulsive disorders, neoplastic disease other than basal cell carcinoma, and significant psychiatric disease.
-
History of glaucoma or cataracts
-
Presence of systemic fungal, bacterial, viral or parasitic infections and/or ocular herpes simplex
-
Unlikely to be compliant, take study medication as directed, complete the diary cards, or attend scheduled clinic visits as required.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (39)
NorthEast Medical Research Associates
🇺🇸North Dartmouth, Massachusetts, United States
The Asthma and Allergy Center
🇺🇸Papillion, Nebraska, United States
Allergy, Asthma & Dermatology Research Center
🇺🇸Lake Oswego, Oregon, United States
Allergy and Asthma Research Groups
🇺🇸Eugene, Oregon, United States
The Allergy Asthma and Sinus Center
🇺🇸Knoxville, Tennessee, United States
Pediatric Allergy/Immunology Assoc.
🇺🇸Dallas, Texas, United States
Pharmaceutical Research and Consulting, Inc.
🇺🇸Dallas, Texas, United States
Allergy and Asthma Associates
🇺🇸Houston, Texas, United States
Clinical Trials of Orange County, Inc.
🇺🇸Orange, California, United States
California Allergy & Asthma
🇺🇸Palmdale, California, United States
Centro Neumologia Pediatrica
🇵🇷Hato Rey, Puerto Rico
Clinical Research Institute
🇺🇸Plymouth, Minnesota, United States
Allergy and Asthma Specialists
🇺🇸Huntington Beach, California, United States
Pediatric Care Medical Group
🇺🇸Huntington Beach, California, United States
Southern California Research
🇺🇸Mission Viejo, California, United States
West Coast Clinical Trials
🇺🇸Long Beach, California, United States
Center for Clinical Trials, LLC
🇺🇸Paramount, California, United States
Integrated Research Group
🇺🇸Riverside, California, United States
Allergy and Asthma Medical Group
🇺🇸Walnut Creek, California, United States
Sneeze, Wheeze and Itch Associates
🇺🇸Normal, Illinois, United States
AeroAllergy Research Labs of Savanna, Inc
🇺🇸Savannah, Georgia, United States
Allergy & Asthma Care of Florida
🇺🇸Ocala, Florida, United States
New Horizon's Health Research
🇺🇸Atlanta, Georgia, United States
Regional Allergy and Asthma Consultants
🇺🇸Asheville, North Carolina, United States
Perez-Betancourt Medical Clinic
🇺🇸Metairie, Louisiana, United States
Allergy & Respiratory Center
🇺🇸Canton, Ohio, United States
Asthma and Allergy Associates, PC
🇺🇸Ithaca, New York, United States
Dayton Clinical Research Center
🇺🇸Dayton, Ohio, United States
St.Elizabeth's Children's Health Center
🇺🇸Utica, New York, United States
Clinical Research Institute of Southern Oregon, PC
🇺🇸Medford, Oregon, United States
Allergy & Clinical Immunology Associates
🇺🇸Pittsburgh, Pennsylvania, United States
Virginia Adult & Pediatric Allergy & Asthma
🇺🇸Richmond, Virginia, United States
Spokane Allergy and Asthma Clinical Research
🇺🇸Spokane, Washington, United States
Ponce School of Medicine
🇵🇷Ponce, Puerto Rico
Allergy Associates Medical Group
🇺🇸San Diego, California, United States
Family Allergy & Asthma Research Institute
🇺🇸Louisville, Kentucky, United States
Dr. Santiago Reyes
🇺🇸Oklahoma City, Oklahoma, United States
Allergy and Asthma Clinical Research Center
🇺🇸Oklahoma City, Oklahoma, United States
Allergy Associates Research Center
🇺🇸Portland, Oregon, United States